PRQR - ProQR Therapeutics N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.04
-0.35 (-4.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.39
Open8.38
Bid8.01 x 800
Ask8.39 x 2200
Day's Range8.00 - 8.49
52 Week Range5.49 - 16.99
Volume144,342
Avg. Volume313,166
Market Cap396.916M
Beta (5Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateFeb 24, 2020 - Mar 01, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.28
  • Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
    Zacks

    Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

    Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.

  • Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%?
    Simply Wall St.

    Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%?

    ProQR Therapeutics N.V. (NASDAQ:PRQR) shareholders might be concerned after seeing the share price drop 11% in the...

  • Did Hedge Funds Drop The Ball On ProQR Therapeutics NV (PRQR) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On ProQR Therapeutics NV (PRQR) ?

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study
    Zacks

    ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study

    ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.

  • Vertex's Kalydeco Gets EU Approval to Treat CF in Infants
    Zacks

    Vertex's Kalydeco Gets EU Approval to Treat CF in Infants

    Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.

  • GlobeNewswire

    ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 Aurora clinical trial of QR-1123 in patients with autosomal dominant retinitis pigmentosa (adRP). “From previous clinical trials we have seen that RNA therapies can be a promising approach for patients with inherited retinal diseases and there is a strong need for novel approaches in diseases that currently have no treatments,” said David G. Birch, Ph.D., Principal Investigator of Aurora and Scientific Director of the Retina Foundation of the Southwest in Dallas, Texas.

  • MarketWatch

    ProQR shares rises on FDA orphan drug designation

    Shares of ProQR Therapeutics rose 10% in premarket trading after it said the Food and Drug Administration had granted an orphan-drug designation to QR-1123. The experimental therapy is being tested as a treatment for vision loss caused by autosomal dominant retinitis pigmentosa (adrp), a rare eye disease. "Our goal is to develop and actively advance a pipeline of programs that can treat inherited retinal diseases like adRP in a targeted manner," ProQR CEO Daniel de Boer said in a news release. ProQR stock is down 51% year-to-date, while the S&P 500 has gone up 24%.

  • GlobeNewswire

    ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. ODD provides a special status for investigational drugs being developed for rare diseases.

  • GlobeNewswire

    ProQR to Present at Upcoming Scientific Conferences

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • GlobeNewswire

    ProQR to Present at Upcoming Investor Conferences

    LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.

  • Were Hedge Funds Right About Dumping ProQR Therapeutics NV (PRQR)?
    Insider Monkey

    Were Hedge Funds Right About Dumping ProQR Therapeutics NV (PRQR)?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]

  • Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates
    Zacks

    Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates

    Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.

  • ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of -9.38% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

    Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1.

  • Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates
    Zacks

    Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates

    Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.

  • BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3
    Zacks

    BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3

    BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.

  • Will ProQR Therapeutics Continue to Surge Higher?
    Zacks

    Will ProQR Therapeutics Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor ProQR Therapeutics.

  • GlobeNewswire

    ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Citigroup Global Markets and Evercore ISI acted as joint bookrunners for the offering.  Cantor Fitzgerald & Co. and JMP Securities acted as lead managers, with Chardan and Kempen acting as co-managers.

  • Benzinga

    The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...

  • GlobeNewswire

    ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

    LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the pricing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day option to purchase up to 1,363,636 additional ordinary shares at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire

    ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

    ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it intends to offer and sell $50,000,000 of its ordinary shares in an underwritten public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional $7,500,000 of ordinary shares, on the same terms and conditions.

  • GlobeNewswire

    ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA) for sepofarsen for the treatment of Leber’s congenital amaurosis 10 (LCA10), the most common cause of blindness due to genetic disease in children.

  • Benzinga

    The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...

  • GlobeNewswire

    ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced positive top-line results from the PQ-110-001 study, a Phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported today that patients receiving sepofarsen had a clinically meaningful improvement in vision, and in some cases the patient’s vision improved to a level that could be deemed life changing. This is very encouraging for the LCA10 community and the Inherited Retinal Disease community as a whole,” said Stephen R. Russell, MD, Schrage Professor of Ophthalmology and Visual Sciences and Principal Investigator at the University of Iowa.

  • GlobeNewswire

    ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

    LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that management will present and discuss top-line results from the Phase 1/2 study of sepofarsen on October 10, ahead of the American Academy of Ophthalmology's annual meeting to be held in San Francisco, CA, U.S. PQ-110-001 is a first-in-human open-label trial that enrolled 5 children (age 6 - 17 years) and 6 adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Two dose levels are being tested, 80 μg (160 μg loading dose) and 160 μg (320 μg loading dose).